Article date: December 2010
By: Gerlinde Egerer, Kathrin Eisenlohr, Martina Gronkowski, Juergen Burhenne, Klaus‐Dieter Riedel, Gerd Mikus, in Volume 70, Issue 6, pages 903-907
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
AIMS
The objective of this investigation was to assess the effect of aprepitant on the pharmacokinetics of high‐dose melphalan used as conditioning therapy before blood stem cell transplantation in multiple myeloma.
METHODS
Aprepitant (125 mg) or placebo was administered 1 h before melphalan therapy (1 h infusion of 100 mg m−2). Eleven plasma samples were obtained over 8 h and melphalan was quantified using an LC/MS/MS method. Standard pharmacokinetic parameters were calculated and nonparametric testing was applied to assess the differences between aprepitant and placebo treatment.
RESULTS
Twenty patients received placebo and 10 patients aprepitant treatment. There were no differences observed for Cmax at the end of melphalan infusion (placebo 3431 ± 608 ng ml−1vs. aprepitant 3269 ± 660 ng ml−1). In addition, AUC and terminal elimination half‐life were not changed by aprepitant. Total clearance of melphalan was 304 ± 58 ml min−1 m−2 (placebo) which was not influenced by aprepitant (288 ± 78 ml min−1 m−2).
CONCLUSIONS
The administration of the NK1 receptor antagonist aprepitant 1 h before a high‐dose chemotherapy does not influence the exposure and the elimination of melphalan. Therefore, oral administration of 125 mg aprepitant 1 h before melphalan infusion does not alter the disposition of intravenously administered melphalan.
DOI: 10.1111/j.1365-2125.2010.03792.x
View this article